" class="no-js "lang="en-US"> Abcam - Medtech Alert
Sunday, October 01, 2023
Abcam | Pharmtech Focus


About Abcam


As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.
Abcam partners with life science organizations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company’s proprietary discovery platforms and world-leading, antibody expertise.
By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company’s pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products.
With 13 sites globally, many of Abcam’s 1,500+ strong team are located in the world’s leading life science research hubs, complementing a global network of services and support.

Related Story

Spirea Raises £2.4M ($3M) to Develop Antibody Drug Conjugates in Cancer

June 15 2022

Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate […]

Alamar Biosciences Partners with Abcam to Drive Understanding of the Human Proteome

January 4 2022

Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the […]

Abcam Completes $340m Strategic Acquisition and Expands Kit Capacity and Capability

October 27 2021

Abcam (AIM:ABC;NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announces the successful completion […]